Xin Lang Cai Jing·2025-10-14 07:35Group 1 - The core point of the news is that BeiGene's stock has experienced a decline of 10.81% over the past four days, with a current price of 273.71 CNY per share and a market capitalization of 421.699 billion CNY [1] - BeiGene was founded on October 28, 2010, and went public on December 15, 2021, focusing on the research, development, production, and commercialization of innovative drugs [1] - The company's main revenue source is from drug sales, accounting for 99.10% of total revenue, while collaboration income contributes 0.90% [1] Group 2 - According to data, one fund under Xinda Australia has a significant holding in BeiGene, specifically the Xin'ao New Target Flexible Allocation Mixed A Fund (003456), which held 600 shares, representing 0.12% of the fund's net value [2] - The fund has incurred a floating loss of approximately 6,264 CNY today, with a total floating loss of 19,900 CNY during the four-day decline [2] - The Xin'ao New Target Flexible Allocation Mixed A Fund was established on October 19, 2016, with a current size of 3.261 million CNY and has achieved a year-to-date return of 3.01% [2]